Pacira BioSciences (PCRX) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Pacira BioSciences (NASDAQ: PCRX):

• 12/22/2025 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/9/2025 – Pacira BioSciences is now covered by analysts at Barclays PLC. They set an “equal weight” rating and a $27.00 price target on the stock.
• 12/8/2025 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Pacira BioSciences was upgraded by analysts at Barclays PLC to a “hold” rating.
• 12/1/2025 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Pacira BioSciences had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Pacira BioSciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
• 11/8/2025 – Pacira BioSciences was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/7/2025 – Pacira BioSciences had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, insider Jonathan Slonin sold 3,960 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $24.09, for a total transaction of $95,396.40. Following the completion of the sale, the insider owned 178,367 shares in the company, valued at $4,296,861.03. This represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Shawn Cross sold 15,896 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $25.03, for a total transaction of $397,876.88. Following the completion of the sale, the chief financial officer owned 56,250 shares of the company’s stock, valued at $1,407,937.50. This trade represents a 22.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 32,920 shares of company stock worth $817,544. Insiders own 6.40% of the company’s stock.

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.